Published on 8 May 2024 on GuruFocus.com via Yahoo Finance
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
Revenue: Reported at $72,000 for Q1 2024, surpassing the estimated $70,000.Net Loss: Recorded at $48.54 million for Q1 2024, below the estimated loss of $62.60 million.Earnings Per Share: Reported a loss of $0.79 per share, surpassing the estimated loss of $1.10 per share.Research and Development Expenses: Totaled $40.94 million, down from $50.74 million in the previous year.General and Administrative Expenses: Decreased to $15.03 million from $21.83 million year-over-year.Total Assets: Increased to $630.38 million as of March 31, 2024, up from $490.42 million at the end of 2023.Cash Position: Cash, cash equivalents, and short-term investments stood at $613.19 million, significantly higher than the $477.37 million at the end of the previous year.
Warning! GuruFocus has detected 3 Warning Signs with VRDN.